Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
US drug major Eli Lilly (NYSE: LLY) says it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals. 2 December 2011
Pharmaceutical
The European Commission has approved drug majors Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca's (LSE: AZN) Onglyza (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycemic) control in adult patients with type 2 diabetes. 29 November 2011
Pharmaceutical
Danish insulin giant Novo Nordisk (NVO: N) has released a video highlighting that, effective yesterday (November 28), it will no longer use living animals to test the quality of the batches of medicine coming out of the company' production lines. These tests have for years been required by health authorities as part of their approval of the products. 29 November 2011
Pharmaceutical
An inexpensive drug that treats type-2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a study by a Michigan State University researcher which appears in the current issue of PloS One (Public Library of Science). 27 November 2011
Pharmaceutical
According to Danish insulin giant Novo Nordisk (NVO: N) diabetes is on the rise in Qatar and poses a serious threat to the health of the nation. According to new data released by the International Diabetes Federation (IDF) Qatar has one of the highest rates of diabetes prevalence in the region; 20.2% of the population now has diabetes, IDF estimates. 24 November 2011
Biotechnology
Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial results from a pivotal Phase III clinical study with its type 1 diabetes drug candidate DiaPep277 show that the study has met its primary endpoint, defined as the change from baseline in C-peptide levels at the end of the study. 22 November 2011
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) released disappointing top-line results from the first of eight Phase III studies of albiglutide to complete in type 2 diabetes (dubbed Harmony 7) comparing its drug with Danish firm Novo Nordisk's (NVO: N) already marketed Victoza (liraglutide). 18 November 2011
Pharmaceutical
The European Medicines Agency says it has been formally notified by Merck Sharp & Dohme (Europe), a subsidiary of US drug giant Merck & Co (NYSE: MRK) of its decision to withdraw its application for a centralized marketing authorization for the medicine Janacti (sitagliptin and pioglitazone) and related trade names, 100/30mg and 100/45mg fixed-dose combination tablets intended to be used for the treatment of adult patients with type 2 diabetes mellitus. 15 November 2011
Pharmaceutical
Independent French drugmaker Laboratoires Servier has entered into an R&D agreement with privately-held Canadian company Prognomix, aimed at identifying novel targets as part of programs meant to develop innovative type 2 diabetes and metabolic disease treatment. 11 November 2011
Pharmaceutical
Merck & Co (NYSE; MRK), the USA's second largest drugmaker, says that its Nexplanon (etonogestrel implant) 68mg, a long-acting, progestin-only single-rod hormonal implanted contraceptive, is now available in the USA. 10 November 2011
Biotechnology
Shares of US biotech firm Amylin Pharmaceuticals fell 8.4% to $10.01 in pre-market trading yesterday, when it was revealed it had agreed to terminate its decade long alliance with drug major Eli Lilly (NYSE: LLY) for the exenatide-based diabetes drugs Byetta and the extended-release version Bydureon, and resolve the outstanding litigation between the companies. 9 November 2011
Pharmaceutical
Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from a 26-week Phase IIIa treat-to-target study comparing DegludecPlus, a soluble combination of ultra-long-acting insulin degludec and insulin aspart, to insulin glargine (Sanofi's blockbuster drug Lantus) in Japanese people with type 2 diabetes inadequately controlled on oral antidiabetic drugs. This is the 18th announced Phase IIIa study in the Degludec and DegludecPlus clinical trial development program. 7 November 2011
Pharmaceutical
Danish drug discovery firm Zealand Pharma (Nasdaq OMX: ZEAL.CO), says that its partner, French drug major Sanofi (Euronext: SAN) has submitted a marketing authorization application for Lyxumia (lixisenatide) in Europe. Lixisenatide is a once-daily GLP-1 receptor agonist discovered by Zealand Pharma and licensed to Sanofi, which is completing Phase III development of the drug as a new treatment for Type-2 diabetes. 4 November 2011
Pharmaceutical
Byetta (exenatide), a drug which has been co-developed and now marketed by US biotech firm Amylin (Nasdaq: AMLN) and drug major Eli Lilly (NYSE: LLY) and commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at Buffalo, USA, study - funded by the two companies - has shown. 4 November 2011
Pharmaceutical
There was good news for Danish insulin giant Novo Nordisk (NVO: N) yesterday, when the European Commission approved the extended use of the firm's basal insulin analogue, Levemir (insulin detemir), in children aged two to five years with type 1 diabetes, making insulin detemir the only basal insulin analogue for use in this young patient group supported by its Summary of Product Characteristics (SmPC). 3 November 2011
Pharmaceutical
The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) said yesterday that the US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet. 2 November 2011
Biotechnology
By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share for the drug class in the G7 markets (USA, France, Germany, Italy, Spain, the UK and Japan). 30 October 2011
Pharmaceutical
Danish insulin giant Novo Nordisk (NVO: N) has reported financial results for the first nine months of 2011, showing that turnover rose 8% to 48.23 billion Danish kroner ($9.0 billion). Shares in Novo Nordisk shares rose 6.6% to 581.50 kroner in morning trading yesterday, outperforming the Copenhagen bourse's blue chip index which was up 4.5%. 28 October 2011
Pharmaceutical
Just as Anglo-Swedish drug major AstraZeneca (LSE: AZN) was about to announce third-quarter 2011 financial results, last evening the company received disappointing news from the US Food and Drug Administration regarding its type 2 diabetes drug candidate dapagliflozin (under development with US partner Bristol-Myers Squibb; NYSE: BMY), with the agency extending the new Prescription Drug User Fee Act (PDUFA) goal date by three months to January 28, 2012. 27 October 2011
Pharmaceutical
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has clarified its opinion on pioglitazone-containing anti-diabetes medicines and the risk of bladder cancer. The Committee confirmed its previous opinion, introducing some clarifications for transparency and consistency purposes: pioglitazone remains a valid treatment option for certain patients with type 2 diabetes, when certain other treatments (metformin) have not been suitable or have failed to work adequately. The new warnings and contraindications recommended in July 2011 remain in place. 24 October 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze